Virtual Library
Start Your Search
E. Soeratman
Author of
-
+
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-067 - Characteristics and Survival Rate of Non-Small Cell Lung Cancer in Patients 45 Years of Age or Younger (ID 8191)
09:30 - 16:00 | Author(s): E. Soeratman
- Abstract
Background:
Lung cancer in younger patients (45 years of age and younger) is rarely found and has different characteristics with older patients. In this study we are looking for characteristics and survival rate of younger NSCLC patients at Indonesia.
Method:
NSCLC patients that came to Dharmais Cancer Center during January 2005 – December 2015 aged 45 years or younger were included in this study. We analyzed patients’ age, gender, history of smoking, histology type, stage, therapy and survival rate.
Result:
Out of 956 NSCLC patients, there were 134 young patients (13.9%). Median age of patient is 39 years old. The most common range of age is 41-45 years old (n=57, 42.5%) with more male patients compared to female patients (n=92, 68.7%). 108 young NSCLC patients (80.6%) did not have history of smoking. Adenocarcinoma is the most common histology type found (59%) and stage IV (52.2%) is most frequent in this study. There is no significant difference between gender and diagnosis (p=0.737), stage (p=0.170), history of smoking and type of histology (p=0.534) in younger NSCLC patients. Median survival rate of the younger patients is 12.2 months (95% CI: 11.045 – 13.355), compared with older patients being 13.2 months (95% CI: 11.547 – 14.853). There is no significant difference between survival rate of younger NSCLC patients and older patients (p=0.543). Patients with EGFR mutation does not have significant association with gender (p=0.07), history of smoking (p=0.259), amount of cigarettes per day (p=0.942), and Brinkman Index (p=0.366). There is a significant difference of survival rate between patients who have EGFR mutation and those who do not (27.4 months VS. 12.2 months; p=0.05). There is no significant difference between patients with EGFR mutation who received target therapy and those who did not (p=0.426). However, there is a significant difference between patients without EGFR mutation who received chemotherapy and those who did not (15.2 months vs. 11.5 months, p=0.05).
Conclusion:
NSCLC in younger patients have shorter survival rate compared with older patients. Survival rate in patients with EGFR mutation who received chemotherapy is better.
